3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Classical hematology
1
CNS
1
Conditions
Venous Thromboembolism
22
Neoplasms
9
Pulmonary Embolism
6
Venous Thrombosis
5
Thrombosis
4
Multiple Myeloma
3
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Upper Extremity Deep Vein Thrombosis
1
Thromboembolism
1
Thrombocytopenia
1
Thrombocythemia, Essential
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Ovarian Neoplasms
1
Neoplasms, Plasma Cell
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Mesenteric Ischemia
1
Lymphoma
1
Leukemia
1
Intracranial Thrombosis
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Glioblastoma
1
Endometrial Neoplasms
1
Embolism
1
Catheter-Related Infections
1
Astrocytoma
1
Interventions
apixaban
1
Temozolomide
1
Rivaroxaban
1
Radiotherapy
1
Long-Term Synaptic Depression
1
Dalteparin
1
Comparative Genomic Hybridization
1
Amplified Fragment Length Polymorphism Analysis
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioma
×
apixaban
×
Classical hematology
×
Clear all
NCT05683808
2026-01-30
VTE-POG
University of Vermont Medical Center
Phase 2
Recruiting
40 enrolled